Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EPS (Weighted Average and Diluted) (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.4 in Q4 2022.

  • For Q4 2022, EPS (Weighted Average and Diluted) fell 129.63% year-over-year to -$0.4; the TTM value through Dec 2022 reached -$1.39, down 201.46%, while the annual FY2025 figure was -$1.94, 3.0% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.4 in Q4 2022 per AVIR's latest filing, down from -$0.1 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.62 in Q4 2020 and bottomed at -$1.74 in Q3 2020.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$0.04, with a median of -$0.36 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 185.0% in 2021, then crashed 2000.0% in 2022.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $2.62 in 2020, then crashed by 48.47% to $1.35 in 2021, then tumbled by 129.63% to -$0.4 in 2022.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.4 in Q4 2022, -$0.1 in Q3 2022, and -$0.38 in Q2 2022.